- Home
- SSKN vs RDHL Comparison
SSKN vs RDHL Comparison
Compare SSKN & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSKN
- RDHL
- Stock Information
- Founded
- SSKN 1989
- RDHL 2009
- Country
- SSKN United States
- RDHL Israel
- Employees
- SSKN N/A
- RDHL N/A
- Industry
- SSKN Medical/Dental Instruments
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- SSKN Health Care
- RDHL Health Care
- Exchange
- SSKN Nasdaq
- RDHL Nasdaq
- Market Cap
- SSKN 9.7M
- RDHL 4.3M
- IPO Year
- SSKN 2005
- RDHL N/A
- Fundamental
- Price
- SSKN $2.44
- RDHL $2.10
- Analyst Decision
- SSKN Strong Buy
- RDHL
- Analyst Count
- SSKN 1
- RDHL 0
- Target Price
- SSKN $6.00
- RDHL N/A
- AVG Volume (30 Days)
- SSKN 15.2K
- RDHL 18.8K
- Earning Date
- SSKN 08-13-2025
- RDHL 08-28-2025
- Dividend Yield
- SSKN N/A
- RDHL N/A
- EPS Growth
- SSKN N/A
- RDHL N/A
- EPS
- SSKN N/A
- RDHL N/A
- Revenue
- SSKN $33,620,000.00
- RDHL $8,042,999.00
- Revenue This Year
- SSKN $3.31
- RDHL $381.91
- Revenue Next Year
- SSKN $9.67
- RDHL N/A
- P/E Ratio
- SSKN N/A
- RDHL N/A
- Revenue Growth
- SSKN 3.30
- RDHL 23.17
- 52 Week Low
- SSKN $2.10
- RDHL $1.71
- 52 Week High
- SSKN $3.80
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- SSKN 50.75
- RDHL 61.27
- Support Level
- SSKN $2.30
- RDHL $2.00
- Resistance Level
- SSKN $2.66
- RDHL $2.08
- Average True Range (ATR)
- SSKN 0.20
- RDHL 0.09
- MACD
- SSKN 0.02
- RDHL 0.03
- Stochastic Oscillator
- SSKN 28.99
- RDHL 100.00
About SSKN Strata Skin Sciences Inc.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.